As clinical evidence mounts for bispecific, VCs back Bicara with $108M series B

With early clinical data showing responses to Bicara’s lead bifunctional molecule in two tumor types, a venture syndicate has backed the biotech in a new $108 million series B round to support further development of the program and a second preclinical bispecific.

Red Tree Venture Capital and RA Capital Management co-led the round, with first-time backers Omega Funds, Bioqube Ventures, Acorn Bioventures and Janus Henderson joining additional prior investors...